Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XTX501 in Metastatic NSCLC and Advanced Solid Tumors
NCT07688577Phase 2Recruiting
- Sponsor
- Xilio Therapeutics
- Start
- Oct 2026
- Primary completion
- Nov 2029
- Countries
- 1
01
Overview
A Phase 2 trial of XTX501 in non-small cell lung cancer (NSCLC), solid tumor, sponsored by Xilio Therapeutics. Started Oct 2026; status: recruiting.
02
Drugs
XTX501
03
Conditions
non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT07688577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07688577.